Imbruvica approval expanded to include graft versus host disease
(HealthDay)—The U.S. Food and Drug Administration on Wednesday expanded approval for the anti-cancer drug Imbruvica (ibrutinib) to include adults with chronic graft versus host disease (cGVHD).
Aug 2, 2017
0
1